Lazertinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 240 mg, 80 mg
Reference Brands: Lazcluze (USA)
Category:
Oncology Cancer Care
Lazertinib is a third‑generation EGFR tyrosine kinase inhibitor used to treat advanced or metastatic non‑small cell lung cancer (NSCLC) in adults whose tumors carry certain EGFR mutations (exon 19 deletions or exon 21 L858R substitution). It blocks abnormal EGFR signaling in cancer cells, inhibiting growth and helping shrink tumors.
Lazertinib is available in Tablets
and strengths such as 240 mg, 80 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lazertinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lazertinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing